OSOlof Sydow

Olof Sydow

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Olof Sydow has a total of 211 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sex Differences in the Allele Distribution of PGLYRP2 Variant rs892145 in Parkinson’s Disease

    by Caroline Ran, Karin Wirdefeldt, Olof Sydow, Per Svenningsson, Rochellys Diaz Heijtz

    Introduction. Parkinson’s disease (PD) is a complex multifactorial disease, involving genetic susceptibility, environmental risk factors, and gene-environmental interactions. The microbiota-gut-brain axis is hypothesized to play a role in the pathophysiology of PD, and peptidoglycan recognition proteins (PGLYRPs), which modulate the gut microbiota, are, therefore, relevant candidate genes for PD. Methods. Using quantitative real-time PCR, we genotyped three PGLYRP variants (rs892145, rs959117, and rs10888557) and performed an association analysis in 508 PD patients and 585 control individuals. We further conducted a meta-analysis of rs892145 and analyzed PGLYRP2 gene expression in lymphocytes from patients with PD and controls. Results. Although initial analysis of the three variants rs892145, rs959117, and rs10888557 and a meta-analysis of rs892145 did not reveal any association between the selected variants and PD, we found an interaction between sex and genotype for rs892145, with a marked difference in the allele distribution of rs892145 between male and female patients. As compared to controls, the T allele was less common in female patients (odds ratio = 0.76, = 0.04) and more common in male patients (odds ratio = 1.29, = 0.04). No difference was found in PGLYRP2 gene expression between PD patients and controls ( = 0.38), nor between sexes ( = 0.07). Discussion. Overall, this genetic screening in Swedish PD patients does not support previous results demonstrating associations of PGLYRP variants with the risk of PD. Meta-analysis of rs892145 revealed pronounced heterogeneity between previously published studies which is likely to have influenced the results. Taken together, the genetic and gene expression analyses suggest a possible link between genetic variants in PGLYRP2 and sex differences in PD. Because of the limited sample size in our study, these results need to be verified in independent cohorts before concluding.


  • Open Access

    Strong association between glucocerebrosidase mutations and Parkinson's disease in Sweden

    by Caroline Ran, Lovisa Brodin, Lars Forsgren, Marie Westerlund, Mehrafarin Ramezani, Sandra Gellhaar, Fengqing Xiang, Camilla Fardell, Hans Nissbrandt, Peter Söderkvist, et al.


  • Open Access

    Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson’s disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs

    by Sven E. Pålhagen, Olof Sydow, Anders Johansson, Dag Nyholm, Bjorn Holmberg, Hakan Widner, Nil Dizdar, Jan Linder, Tove Hauge, Rasmus Jansson, et al.


  • Open Access

    No Association Between rs7077361 in ITGA8 and Parkinson’s Disease in Sweden

    by Caroline Ran, Rawand Naiel Mehdi, Camilla Fardell, Fengqing Xiang, Hans Nissbrandt, Olof Sydow, Karin Wirdefeldt, Andrea Carmine Belin

    Background: Integrin alpha 8 (ITGA8) encodes the alpha 8 subunit of the integrin alpha8beta1 protein and has recently been suggested as a new candidate gene for Parkinson’s disease, an age related neurodegenerative disease with unknown etiology. ITGA8 is a transmembrane protein involved in several cellular processes, such as cell adhesion, migration and cytoskeletal rearrangement.Objective: Screen a Swedish case control material for rs7077361, a genetic variant in ITGA8, in order to investigate its possible implication in Parkinson’s disease in Sweden.Method: Rs7077361 was genotyped using TaqMan quantitative Real-time PCR and tested for association using appropriate statistical methods.Results: We have screened 502 Swedish Parkinson patients and 599 healthy control individuals for rs7077361 in ITGA8. This genetic variant was in Hardy Weinberg equilibrium in the Swedish population. Allele and genotype frequencies were highly similar between the patients and controls and statistical testing showed that this genetic maker did not associate with Parkinson’s disease (p=0.67).Conclusion: Our results do not support the hypothesis of ITGA8 as a candidate gene for Parkinson’s disease in Sweden.


  • Open Access

    The HLA-DRA variation rs3129882 is not associated with Parkinson's disease in Sweden

    by Caroline Ran, Thomas Willows, Olof Sydow, Anders Johansson, Peter Söderkvist, Nil Dizdar, Ahmad Ahmadi, Lars Olson, Andrea Carmine Belin


  • Open Access

    Selecting deep brain stimulation or infusion therapies in advanced Parkinson’s disease: an evidence-based review

    by Jens Volkmann, Alberto Albanese, Angelo Antonini, K. Ray Chaudhuri, Carl E. Clarke, Rob M. A. Bie, Günther Deuschl, Karla Eggert, Jean-Luc Houeto, Jaime Kulisevsky, et al.

    Motor complications in Parkinson’s disease (PD) result from the short half-life and irregular plasma fluctuations of oral levodopa. When strategies of providing more continuous dopaminergic stimulation by adjusting oral medication fail, patients may be candidates for one of three device-aided therapies: deep brain stimulation (DBS), continuous subcutaneous apomorphine infusion, or continuous duodenal/jejunal levodopa/carbidopa pump infusion (DLI). These therapies differ in their invasiveness, side-effect profile, and the need for nursing care. So far, very few comparative studies have evaluated the efficacy of the three device-aided therapies for specific motor problems in advanced PD. As a result, neurologists currently lack guidance as to which therapy could be most appropriate for a particular PD patient. A group of experts knowledgeable in all three therapies reviewed the currently available literature for each treatment and identified variables of clinical relevance for choosing one of the three options such as type of motor problems, age, and cognitive and psychiatric status. For each scenario, pragmatic and (if available) evidence-based recommendations are provided as to which patients could be candidates for either DBS, DLI, or subcutaneous apomorphine.


  • Association of a protective paraoxonase 1 (PON1) polymorphism in Parkinson's disease

    by Andrea Carmine Belin, Caroline Ran, Anna Anvret, Silvia Paddock, Marie Westerlund, Anna Håkansson, Hans Nissbrandt, Peter Söderkvist, Nil Dizdar, Ahmad Ahmadi, et al.


  • Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease

    by S. E. Pålhagen, N. Dizdar, T. Hauge, B. Holmberg, R. Jansson, J. Linder, D. Nyholm, O. Sydow, M. Wainwright, H. Widner, et al.

    Background This interim 12‐month analysis is a part of an open‐label, observational, prospective study on health outcomes and cost impact of levodopa/carbidopa intestinal gel (LCIG, Duodopa) in Parkinson disease (PD). The specific aim was to investigate clinical and health‐related quality of life (HRQoL) effects in routine care. Methods Unified PD rating scale (UPDRS) was the primary efficacy measurement. PD QoL questionnaire 39 (PDQ‐39) assessed HRQoL. Subjects were assessed at baseline, ≥3 months after surgery, and then every 3 months. Results Twenty‐seven treatment‐naïve subjects when started with LCIG showed a decrease in UPDRS score that was statistically significant throughout the year: UPDRS total score (mean ± SD), baseline = 52.1 ± 16.1, N = 27, month 0 (first visit; at least 3 months after permanent LCIG) = 43.1 ± 16.7, N = 27, P = 0.003; month 12 = 42.5 ± 22.6, n = 25, P = 0.017. PDQ‐39 results also showed a tendency for improvement: PDQ‐39 (mean ± SD), baseline = 33.6 ± 10.8, N = 27, month 0 = 27.1 ± 11.8, N = 27, P = 0.001; 12 months = 28.8 ± 12.8, n = 23, P = 0.126. Conclusions LCIG provides functional improvement beginning at first visit that is sustained for 12 months.


  • Open Access

    Genetic Screening of the Mitochondrial Rho GTPases MIRO1 and MIRO2 in Parkinson’s Disease

    by Anna Anvret, Caroline Ran, Marie Westerlund, Olof Sydow, Thomas Willows, Lars Olson, Dagmar Galter, Andrea Carmine Belin

    MIRO1 and MIRO2 (mitochondrial Ras homolog gene family, member T1 and T2) also referred to as RHOT1 and RHOT2, belong to the mitochondrial Rho GTPase family and are involved in axonal transport of mitochondria in neurons. Because mitochondrial dysfunction is strongly implicated in Parkinson’s disease (PD), MIRO1 and MIRO2 can be considered as new candidate genes for PD. We analyzed two non-synonymous polymorphisms and one synonymous polymorphism in MIRO1 and two non-synonymous polymorphisms in MIRO2, in a Swedish Parkinson case-control material consisting of 241 patients and 307 neurologically healthy controls. None of the analyzed polymorphisms in MIRO1 and MIRO2 were significantly associated with PD. Although we did not find a significant association with PD in our Swedish case-control material, we cannot exclude these Rho GTPases as candidate genes for PD or other neurodegenerative disorders.


  • Genetic studies of the protein kinase AKT1 in Parkinson's disease

    by Caroline Ran, Marie Westerlund, Anna Anvret, Thomas Willows, Olof Sydow, Dagmar Galter, Andrea Carmine Belin